Just a moment, the page is loading...
The Supported Studies Programme

For the latest updates on GSK’s response to COVID-19, please click here.



[Anemia of Chronic Kidney Disease (CKD) ISS/SCS Committee (US proposals only). Last updated in November 2023.]
• Benefits and risks of target Hb 10-11.5g/dl
• Outcomes in certain populations with anemia of CKD (non-iron replete, inflammation, transplant)
• Personalized Hb targets and outcome in dialysis populations
• Post transplant anemia

[Chronic Hepatitis B (CHB) Supported Studies Committee. Last updated in June 2023.]
•   Understanding the patient perspective on unmet need in CHB
•   Understanding subpopulations in CHB with greatest need for improved outcomes e.g. those at most risk from HCC
•   Understanding impact of reduced access to care on outcomes in underserved populations with CHB
•   Understanding low diagnosis rates in CHB, impact to outcomes and opportunities to improve
•   Understanding the impact of CHB on patient-important outcomes, including functional cure
•   Measuring value of functional cure versus viral suppression in CHB
•   Understanding the biological mechanisms that lead to functional cure, including heterogeneity of virological and immunological effects
•   Societal and cultural impacts on treatment decision making
•   HBsAg qualitative versus quantitative assessment in CHB – role in improving CHB management and outcomes

[Primary Biliary Cholangitis (PBC) Supported Studies Committee. Last updated in June 2023.]
• Implementing/assessing care pathways that deploy quality-of-life measures and/or symptom assessments into routine clinical care of patients with PBC
• Investigating the mechanism of disease of cholestatic pruritus: basic and clinical research into the interplay of biomarkers, for example bile acids and LPA/autotaxin
• Improving the capture of patient reported outcomes in national/international PBC registries, to increase the understanding of the severity, and quality of life impact, of symptoms of PBC

Although GSK are more likely to support studies aligned to our current areas of interest for supported studies, we are interested in supporting studies that are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology.

© 2001-2024 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.